LENEXA, Kan.--(BUSINESS WIRE)--Evogen, Inc. promoted Richard St.Clair to Vice President of Commercialization.
St.Clair previously served as Director of Marketing & Business Development. In this new assignment, he will be responsible for spearheading efforts for identification of opportunities and commercialization of Evogen and Sceptor products for the healthcare, biodefense, and industrial business segments.
In his previous position as Director, St.Clair was instrumental in creating customer alliances leading to identification of product needs and delivering real world solutions to save customers money while gaining sensitivity and specificity necessary for critical sample collection and analysis.
Utilizing wide-reaching contacts, St.Clair is experienced and has proven successful in managing the customer relationship and all phases of product life cycle including taking products from ideation and development to market launch, and rationalization of product portfolios to revitalize mature products or divest those that have reached the end of their life cycle. He holds a BA degree in human biology from the University of Kansas and an MBA from Webster University.
“We are very pleased to welcome Rich to the executive management team. His knowledge of the industry, practical experience and leadership will be great assets as we expand our market presence,” said Hans Kastensmith, President and CEO of Evogen.
About Evogen, Inc.
Evogen is dedicated to meeting the molecular diagnostic collection and detection needs of a diverse range of customers. The Evogen portfolio includes DNA sample extraction platforms and methodologies, air collection and monitoring and proprietary PCR probe technology which provide the user reliable, sensitive and specific answers. Through careful analysis of the specific needs of each customer, Evogen is able to deliver systems and solutions that provide rapid results while lessening the impact on workflow in the laboratory. Visit Evogen.com
About Sceptor Industries, Inc.
Sceptor provides advanced biological system platforms, assays and reagent kits, and services to detect and identify biological threat agents. These detection and identification systems are used by the Federal Government and major systems integrators within the biodefense industries for a range of specialist applications including building security, civil defense, and military force protection. These biodetection systems are distinguished from competition by their superior performance, stability, ease of use, and affordability.